

Home > > Rx Pharmaceutical > PROLENSA (bromfenac ophthalmic solution) 0.07% > About Prolensa

PROLENSA (bromfenac ophthalmic solution) 0.07%



PROLENSA[®]
(bromfenac ophthalmic solution) 0.07%

About **PROLENSA**

PROLENSA



PROLENSA: An FDA-approved Brand

Product Attributes	PROLENSA ¹
Treats inflammation and pain after cataract surgery	✓
No generic equivalent	✓
Established safety profile	✓
No shaking required	✓
Consistent dose in each drop	✓

INDICATION FOR PROLENSA (bromfenac ophthalmic solution) 0.07%

PROLENSA (bromfenac ophthalmic solution) 0.07% is a nonsteroidal anti-inflammatory drug (NSAID) indicated to treat inflammation and reduce eye pain in patients after cataract surgery.

IMPORTANT SAFETY INFORMATION ABOUT PROLENSA

PROLENSA contains sodium sulfite, a substance that may cause allergic reactions, some severe, in certain people. In addition, tell your doctor if you have had an allergic reaction to any other medications.

Slow or delayed healing may occur while using non-steroidal anti-inflammatory drugs (NSAIDs) such as PROLENSA.

Use of NSAIDs in the eye may result in certain serious eye conditions that can be sight threatening. Tell your doctor immediately about any side effect that you may have.

Replace bottle cap after using and do not touch dropper tip to any surface in order to avoid contamination of the bottle.

Remove contact lenses prior to using PROLENSA. The preservative in PROLENSA, benzalkonium chloride, may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of PROLENSA.

If more than one eye medicine is being used, use the eye medicines at least 5 minutes apart.


The most common side effects (seen in 3%-8% of patients) were inflammation of the eye, foreign body sensation, eye pain, light sensitivity, and blurred vision.

Please click here for [Prescribing Information about PROLENSA](#).

You are encouraged to report side effects of prescription drugs to the FDA. Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

Reference: 1. PROLENSA Prescribing Information, April 2013.
2. Walters TR, Goldberg DF, Peace JH, Gow JA; for the Bromfenac Ophthalmic Solution 0.07% Once Daily Study Group. Bromfenac ophthalmic solution 0.07% dosed once daily for cataract surgery: results of 2 randomized controlled trials. Ophthalmology. 2014;121(1):25-33.

IPR2015-01099 Lupin EX1153
IPR2015-01097 Page 1
IPR2015-01100
IPR2015-01105

Vision and Age
Eye Infections & Irritations
Diseases and Disorders
Find a Doctor
 Eye Exam Check List

Contact Lenses
Contact Lens Care
Dry Eye Products
Allergy/Redness Relief
Rx Pharmaceutical
Eye Vitamins
Surgical Products
Vision Accessories

Contact Us
Customer policies and forms
Rebate Center
Worldwide Locations

Legal Notice
Privacy Policy
Safety Data Sheets (SDS)

Newsroom
Careers
Investor Relations
Grants & Contributions

© 2016 Bausch & Lomb Incorporated.

All information and materials on this site pertain to the U.S. only, unless otherwise indicated.